InsidersTradesSigma
Follow the Acorda Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 20 March 2023 (Acquisition). Among the most active insiders: COHEN RON. Every trade is free.
Analysts rate Acorda Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for neurological diseases. It is listed on the NASDAQ under the ticker ACOR.